

# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Perfluorohexyloctane Ophthalmic Solution (Miebo)

Notes: ^ Adequate trial is defined as 3 months treatment duration \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

**Initiation (new start) criteria:** Non-formulary **perfluorohexyloctane ophthalmic solution (Miebo)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is an ophthalmologist, optometrist or rheumatologist
- Patient has a diagnosis of dry eye disease
- Treatment failure of an ophthalmic wetting agent in the form of drops, ointments, or gels
- Patient has failed an adequate trial<sup>^</sup> of cyclosporine 0.05% ophthalmic emulsion and 0.09% solution

kp.org

Revised: 03/14/24  
Effective: 05/16/24

All plans offered and underwritten by  
Kaiser Foundation Health Plan of the Northwest